D’Aiello, A.; Lin, J.; Gucalp, R.; Tabatabaie, V.; Cheng, H.; Bloomgarden, N.A.; Tomer, Y.; Halmos, B.
Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers 2021, 13, 1464.
https://doi.org/10.3390/cancers13061464
AMA Style
D’Aiello A, Lin J, Gucalp R, Tabatabaie V, Cheng H, Bloomgarden NA, Tomer Y, Halmos B.
Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers. 2021; 13(6):1464.
https://doi.org/10.3390/cancers13061464
Chicago/Turabian Style
D’Aiello, Angelica, Juan Lin, Rasim Gucalp, Vafa Tabatabaie, Haiying Cheng, Noah A. Bloomgarden, Yaron Tomer, and Balazs Halmos.
2021. "Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort" Cancers 13, no. 6: 1464.
https://doi.org/10.3390/cancers13061464
APA Style
D’Aiello, A., Lin, J., Gucalp, R., Tabatabaie, V., Cheng, H., Bloomgarden, N. A., Tomer, Y., & Halmos, B.
(2021). Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. Cancers, 13(6), 1464.
https://doi.org/10.3390/cancers13061464
